Nervous System News and Research

Latest Nervous System News and Research

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients was launched today in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

31 Aug 2009

Psychogenics and Astrazeneca sign agreement to identify new compounds for treating Central Nervous System disorders

PsychoGenics Inc. and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous System (CNS) disorders.

31 Aug 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

Scientists explore the fundamental basis of the lateral-line sensory system

Fish and some amphibians possess a unique sensory capability in the so-called lateral-line system. It allows them, in effect, to "touch" objects in their surroundings without direct physical contact or to "see" in the dark. Professor Leo van Hermmen and his team in the physics department of the Technische Universitaet Muenchen are exploring the fundamental basis for this sensory system. What they discover might one day, through biomimetic engineering, better equip robots to orient themselves in their environments.

29 Aug 2009

New compound discovered by Scripps scientists offers a novel template for drug development

Scientists at Scripps Institution of Oceanography at UC San Diego and their colleagues at Creighton University have deciphered the highly unusual molecular structure of a naturally produced, ocean-based compound that is giving new understanding of the function of mammalian nerve cells.

29 Aug 2009

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Biotie announced today that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.

28 Aug 2009

Carbon nanotubes may help regrow nerve tissue according to a research study

Carbon nanotubes hold many exciting possibilities, some of them in the realm of the human nervous system. Recent research has shown that carbon nanotubes may help regrow nerve tissue or ferry drugs used to repair damaged neurons associated with disorders such as epilepsy, Parkinson's disease and perhaps even paralysis.

28 Aug 2009

AVANIR raises funds to develop and commercialize Zenvia for PBA

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced it had raised gross proceeds of approximately $10.6 million via the sale of approximately 4.5 million shares of common stock at a weighted average price of $2.34 per share.

28 Aug 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Polycystic ovary syndrome, a common condition among women, can be relieved by the use of acupuncture and exercise. This has been shown by a recent study at the Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Aug 2009

High DHA levels aid in learning and mental development of school children

Getting ready for the start of a new school year traditionally means shopping trips for crisp, new clothes and backpacks bursting with fresh school supplies. But how do you prepare your child mentally and physically for the demands of hectic schedules and endless homework? It's easy for children, be it primary graders or teenagers, to anticipate the beginning of class with both excitement and some anxiety. These stress factors can quickly turn to feelings of being overwhelmed and frustrated as schoolwork and activities intensify.

27 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

Sabril (vigabatrin) Oral Solution receives approval from FDA

Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to 2 years. Sabril is the first drug in the United States approved to treat the disorder, characterized by a severe type of seizure that usually appears in the first year of life, typically between ages 4 months and 8 months.

26 Aug 2009

Australian researchers to discover proteins that cause multiple sclerosis

Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

Venlafaxine alleviates depressive symptoms

The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to investigate whether patients with depression benefit from taking drugs belonging to the selective serotonin and norepinephrine reuptake inhibitor (SNRI) drug class.

25 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Mark Booth joins Orexigen Therapeutics as the Chief Commercial Officer

Orexigen((R)) Therapeutics, Inc. today announced that Mark Booth has joined the Company as Chief Commercial Officer. Mr. Booth brings over 25 years of commercial and business development experience to Orexigen. Most recently he served as President of Takeda Pharmaceuticals North America (TPNA) where he presided over the commercial, medical and scientific affairs, business development and all support functions.

25 Aug 2009

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies).

25 Aug 2009

Nervous System News and Research

Latest Nervous System News and Research

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

Psychogenics and Astrazeneca sign agreement to identify new compounds for treating Central Nervous System disorders

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Scientists explore the fundamental basis of the lateral-line sensory system

New compound discovered by Scripps scientists offers a novel template for drug development

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Carbon nanotubes may help regrow nerve tissue according to a research study

AVANIR raises funds to develop and commercialize Zenvia for PBA

Alexza completes acquisition of Symphony Allegro after sharholders' approval

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

High DHA levels aid in learning and mental development of school children

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Sabril (vigabatrin) Oral Solution receives approval from FDA

Australian researchers to discover proteins that cause multiple sclerosis

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Venlafaxine alleviates depressive symptoms

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Mark Booth joins Orexigen Therapeutics as the Chief Commercial Officer

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Nervous System News and Research

Latest Nervous System News and Research

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Newsletters you may be interested in